Vnc-152-102 - An Open-Label, Multicenter Phase 1 Dose Escalation Study To Characterize Safety, Tolerability, Preliminary Antitumor Activity, Pharmacokinetics, And Maximum Tolerated Dose Of Vip152 In Subjects With Relapsed/Refractory Chronic Lymphocytic Le
Posted Date: Mar 31, 2022
- Investigator: Emily Curran
- Specialties: Cancer, Oncology
- Type of Study: Drug
The purpose of this study is to determine the safety, tolerability, pharmacokinetics, maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) of VIP152 (BAY 1251152) as monotherapy or in combination in patients with solid tumors and aggressive non-hodgkin's lymphoma (NHL).
To Be Eligible: Patients With A Histologically Or Cytologically Confirmed Solid Tumor Or Aggressive Nhl Who Are Refractory To Or Have Exhausted All Available Therapies With Myc Expression Or Known C-Myc Amplification/Alterations, Adequate Bone Marrow, Liver, And Renal Functions, Eastern Cooperative Oncology Group (Ecog) Performance Status Of 0 To 2, No Active Clinically Serious Infections Of Events > Grade 2, No Subjects Who Have New Or Progressive Brain Or Meningeal Or Spinal Metastases, No Anticancer Chemotherapy Or Immunotherapy During The Study Or Within 1 Weeks Prior To The First Dose Of Study Drug, No Major Surgery Or Significant Trauma Within 4 Weeks Before The First Dose Of Study Drug, No Allogeneic Bone Marrow Transplant Or Stem Cell Rescue Within 4 Months Before First Dose Of Study Drug; Patients Must Have Completed Immunosuppressive Therapy Before Enrollment.
Phase 1, Leukemia, Cancer
For More Information:
Uc Cancer Center